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ABSTRACT
The epidemiology, and clinical and microbiological spectrum, of infective endocarditis (IE) in Greece
was analysed in a prospective 4-year study in a tertiary hospital and a heart surgery centre in Athens. In
total, 101 cases of IE (71 men, 30 women, aged 54.4 ± 17.1 years) were studied, with a follow-up period
of 3 months. Seventy-seven cases were deﬁnite and 24 possible; 59 involved native valves (native valve
endocarditis; NVE), 31 prosthetic valves (prosthetic valve endocarditis; PVE), of which nine were early
and 22 late, and 11 permanent pacemakers (pacemaker endocarditis; PME). There was a predominant
involvement of aortic (48 ⁄ 101) and mitral (40 ⁄ 101) valves. Seven patients had rheumatic valvular
disease, two had mitral valve prolapse, and eight had a previous history of IE. Thirteen and six patients
had undergone dental and endoscopic procedures, respectively. In 13 patients, intravenous catheters
were used within the 3 months before diagnosis of IE. There were three intravenous drug users among
the patients. Staphylococcus aureus was the most important pathogen, isolated in 22% of cases, followed
by viridans streptococci (19%) and coagulase-negative staphylococci (16%). Enterococcus spp. were
responsible for 3%, HACEK group for 2%, and fungi for 6% of cases. Viridans streptococci were the
leading cause of NVE (29%), Staphylococcus epidermidis of PVE (16%), and S. aureus of PME (54.5%). Six
of 22 S. aureus and ten of 16 S. epidermidis isolates were methicillin-resistant. Surgical intervention,
including total pacemaker removal, was performed in 51.5% of patients. Overall mortality was 16%, but
was 29%with PVE, and was signiﬁcantly higher with medical than with combined surgical and medical
therapy (24.5% vs. 8%). Compared with previous studies, there were changing trends in the
epidemiology, microbiology, treatment and prognosis of IE in Greece.
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INTRODUCTION
Infective endocarditis (IE) [1–4] is an infection of
the cardiac valves or mural endocardium caused
by bacteria, fungi and, less commonly, rickettsiae,
chlamydiae, mycoplasmas and possibly viruses.
This term is more precise than the older term
‘bacterial endocarditis’, since it includes the entire
spectrum of microorganisms that affect the endo-
cardium.
Before the antibiotic era, IE was a progressive,
incurable disease with fatal outcome that affected
primarily young people. However, in the last
50 years, widespread use of antibiotics and
advancements in cardiac surgery have contribu-
ted to major changes. First, there has been a
signiﬁcant decrease in mortality, provided that an
early diagnosis is established and appropriate
treatment is administered as soon as possible.
Second, the population susceptible to IE and the
causative infectious agents have changed. More
speciﬁcally, the incidence of rheumatic valvular
disease has decreased dramatically, while the
proportion of individuals with prosthetic cardiac
valves or a permanent pacemaker (PM), together
with the number of immunocompromised
patients, is increasing continuously. This has
resulted in an increase to > 50 years in the mean
age of patients with IE. Another change is the
widespread use of intravenous drugs and the
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increase in the proportion of patients with under-
lying mitral valve prolapse [1–4]. Despite all the
above, it seems that the incidence of the disease
(20–31 cases ⁄ 1 000 000 population ⁄ year) [2,4–6]
has remained constant compared to the pre-
antibiotic era.
During recent years there have also been
changes in the diagnosis of the disease. New
infectious causative agents have been recognised.
The development of new laboratory techniques
and improvements in the older methods have
disclosed the role of many new pathogens, such
as Coxiella burnetii, Brucella, Bartonella and fungi.
Also, the development of echocardiography, and
its contribution to the establishment of the Duke
diagnostic criteria, has constituted an important
advance towards better diagnosis [1–4].
This paper describes a prospective study of 101
IE cases in Greece, concentrating on the epidemi-
ology, causative microorganisms, treatment and
prognosis, with a follow-up period of 3 months
after diagnosis of IE.
PATIENTS AND METHODS
This was a prospective 4-year study of 101 patients with IE
who were hospitalised in the Internal Medicine, Cardiology
and Cardiosurgery Departments of Evangelismos General
Hospital and Onassio Cardiac Surgery Centre in Athens,
Greece.
From 1997 to 2000, the infectious diseases team recorded all
data for every patient with IE for whom an infectious diseases
specialist’s consultation was requested. Data included the
infected intracardiac site, the nature of the infected valve
(native or prosthetic), the presence of predisposing factors,
clinical characteristics, the causative microorganisms, the
treatment regimens (including surgical intervention) and the
outcome, with a follow-up period of 3 months after diagnosis.
The Duke diagnostic criteria [7] were used for case
deﬁnition, with cases classiﬁed as deﬁnite or possible. In the
case of PM endocarditis (PME), the above criteria were
modiﬁed according to Klug et al. [8]. Prosthetic valve
endocarditis (PVE) cases were considered as ‘early’ if they
occurred during the ﬁrst 2 months after valve replacement,
and ‘late’ if they appeared thereafter. Endocarditis cases
related to PM lead infection were considered ‘acute’ if
symptoms occurred within the ﬁrst 6 weeks after the last
procedure on the implant site (i.e., ﬁrst implantation, lead
replacement, elective PM replacement, PM exteriorisation) and
‘chronic’ if they occurred later [8]. Causative microorganisms
were identiﬁed by conventional culture and serology. Blood
cultures were performed on the BACTEC system. MacCon-
key’s, blood and chocolate agar, and Sabouraud’s medium,
were used for tissue or device cultures. MICs of commonly
used antibiotics for the isolated microorganisms were deter-
mined by the Etest method.
Chi-square tests were used for analysing data. A p value of
< 0.05 was considered to be signiﬁcant.
RESULTS
Seventy-ﬁve of the 101 patients were recruited
from the Cardiology or Internal Medicine Depart-
ments, and 26 from the Cardiosurgery Depart-
ments, where they were referred for assessment of
potential surgical intervention after IE diagnosis.
Seventy-one were male and 30 were female, with
ages ranging from 17 to 86 years (mean
54.4 ± 17.1 years). According to the Duke diagnos-
tic criteria, 77 of the cases were deﬁnite and
24 possible. Fifty-nine involved native valves
(native valve endocarditis; NVE), 31 involved
prosthetic valves (PVE), and 11 were associated
with the lead of a permanent PM (PME).
Table 1 lists the valves (or other intracardiac
sites) affected. Seven patients had a previous
history of rheumatic heart disease, two had mitral
valve prolapse, and one had a ventricular septal
defect. Of the PVE cases, nine were early and 22
late. Among the PME cases, the presentation was
acute in two patients and chronic in nine patients.
Eight patients had a previous history of endocar-
ditis.
The factors predisposing to bacteraemia are
listed in Table 2. The preceding period of
3 months was only approximate because the
precise onset of IE was often difﬁcult to deﬁne.
Sixteen patients had impaired immunity because
of either diabetes mellitus (11 patients), malignant
diseases (two), autoimmune disease (two), or
corticosteroid therapy (one).
Causative microorganisms isolated from blood,
tissue or device cultures, or for which serology
was positive, are listed in Table 3. Six (27%) of the
22 Staphylococcus aureus isolates and ten (62.5%)
of the 16 Staphylococcus epidermidis isolates were
Table 1. Valve (or other intracardiac structure) involve-









Aortic 28 20 48 (48)
Mitral 29 11 40 (40)
Tricuspid 5 – 5 (5)
Pulmonary 1 1 2 (2)





Total 65 32 11 108a
aSeven patients had two simultaneous intracardiac structures (aortic + mitral, six;
pacemaker + tricuspid, one).
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methicillin-resistant. The two non-viridans strep-
tococcal isolates were Streptococcus pyogenes and
Streptococcus bovis. Enterobacteriacae isolated
were Klebsiella pneumoniae (one case) and Enterob-
acter spp. (two), while HACEK group isolates
were Haemophilus inﬂuenzae and Actinobacillus
actinomycetemcomitans (one case each). For seven
NVE and 11 PVE cases, cultures were negative
and the serology was inconclusive.
Antimicrobial treatment was intravenous
initially,with aduration ranging from4 to 8 weeks.
For staphylococci, streptococci and enterococci, a
combination of a b-lactam or glycopeptide with an
aminoglycoside was administered (according to
susceptibility tests, with additional oral rifampicin
for staphylococcal PVE). For cases of fungal endo-
carditis, liposomal amphotericin was adminis-
tered, either alone or in combination with
ﬂucytosine or ﬂuconazole. Individualised treat-
ment was given for all remaining IE cases (Brucella,
Listeria, Q fever, etc.). In these cases, initial intra-
venous treatment was followed by oral antibiotics
for a total duration of at least 3 months (several
years for cases of Coxiella and fungal endocarditis).
For cases with negative cultures and serology,
epidemiological data determined the standard
empirical treatment given. In 18 patients, antibiotic
regimensweremodiﬁedbecauseof adverse events,
namely allergic reactions to b-lactams (eight cases),
renal problems with aminoglycosides or vanco-
mycin (seven), drug-related fever (two), and neu-
tropenia (one). Twenty-seven of the patients
suffered arterial emboli (infarction or abscess), 16
in brain, 13 in spleen, six in lungs, and two in the
lower limbs.
Surgical intervention (valve replacement or
total PM system removal) occurred with 52 of
the 101 patients (Table 4). Valve replacement was
performed mainly because of cardiac complica-
tions, fungal IE and ⁄ or large vegetations, and
organisms with poor response to antibiotics.
Patients with PME had the PM system removed,
except for two patients who died before lead
ablation, and another two patients whose general
condition precluded surgery. The prognosis for
endocarditis is shown in Table 5. Of the cases with
a fatal outcome, 5 ⁄ 5 with NVE, 5 ⁄ 9 with PVE and
2 ⁄ 2 with PME were receiving medical treatment
Table 2. Conditions predisposing to bacteraemia
Condition Number of cases
Medical or dental manipulationsa
Dental procedures 13




Intravenous drug use 3
Skin or pulmonary infectiona 4
Early (< 2 months) valve replacement 9
Permanent pacemaker implantation 11
None speciﬁed 46
Total 105b
aDuring the preceding 3 months.
bFour patients had more than one predisposing condition.










Staphylococcus aureus 13 3 6 22
Staphylococcus epidermidis 7 5 4 16
Viridans streptococci 17 2 – 19
Other streptococci 2 – – 2
Enterococcus spp. 3 – – 3
HACEK group 1 1 – 2
Enterobacteriaceae 1 1 1 3
Pseudomonas spp. – 2 – 2
Acinetobacter spp. 1 – – 1
Campylobacter spp. – 1 – 1
Corynebacterium spp. – 1 – 1
Brucella melitensisa 2 – – 2
Coxiella burnetiia 1 – – 1
Listeria monocytogenesa – 1 – 1
Propionibacterium acnes – 1 – 1
Candida spp. 3 2 – 5
Aspergillus spp. 1 – – 1
Negative culture and
serology
7 11 – 18
Total 59 31 11 101
aIdentiﬁed by serological tests.
Table 4. Patients with infective endocarditis who under-
went surgical intervention during the 3-month follow-up
period
Surgical intervention
Yes No Total Intervention (%)
Native valves 28 31 59 47
Prosthetic valves 17 14 31 55
Pacemaker 7 4 11 64
Total 52 49 101 51.5
Table 5. Prognosis for patients with infective endocarditis
during the 3-month follow-up period
Number of cases
Improvement/cure Death Total Mortality rate (%)
Native valves 54 5 59 8.5
Prosthetic valves 22 9 31 29
Pacemaker 9 2 11 18
Total 85 16a 101 16
aTwelve (24.5%) of 49 cases treated medically and four (8%) of 52 cases treated
surgically + medically, p < 0.05.
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alone. The overall mortality was 24.5% for
medical treatment, compared with 8% for com-
bined medical and surgical treatment (p < 0.05).
DISCUSSION
The study group included patients from a tertiary
care hospital and a cardiac surgery centre, to
which many patients were referred from other
hospitals. This fact may cause a selection bias,
resulting in some limitations to the interpretation
of the results. The study group also included a
large proportion of PVE (31%), which in other
studies has ranged from 14% to 31% [6,7,9–12].
The proportion of early PVE (generally reﬂecting
contamination during the peri-operative period)
was 29%, and that of late PVE (occurring after
valve epithelialisation and having similar patho-
genetic mechanisms to those of NVE) was 71%
[2,13]. The series also included a signiﬁcant pro-
portion of PME (11%), which in most other studies
is very small or non-existent [7,10,11]. PME is a rare
but severe complication of permanent cardiac PMs
[8,14–18]. Chemoprophylaxis during PM implan-
tation seems to decrease the above risk [19], but is
not used widely. In the present study, the precise
number of patients who received prophylaxis
during implantation was not known, since this
procedure was done in various institutions. How-
ever, taking into account the signiﬁcant number of
cases of PME, it may be prudent to suggest
prophylaxis as a routine practice during PM
implantation. According to the American Heart
Association [20] and the International Society for
Chemotherapy [21], the presence of a permanent
PM does not constitute a high- or moderate-risk
justifying chemoprophylaxis before invasive den-
tal or medical operations.
In this study, IE affected mostly middle-aged
men (mean age 54.5 years; male ⁄ female ratio of
2.5:1). The valve involved most commonly was
the aortic valve (47.5% in this study; 62% in the
literature [9]). More speciﬁcally, in PVE cases the
aortic valve was involved more frequently, while
involvement of the mitral valve predominated
slightly in NVE. The disease involved more than
one valve, or valve and PM, in 7% of the study
group, compared with a ﬁgure of 15% reported
previously [9]. The proportion of patients with
rheumatic heart disease was very low (7%). This
can be explained by the broad use of antibiotics,
resulting in a decrease in the incidence of rheu-
matic fever during the last few decades. Strom
et al. [11] also found a low percentage (12%).
Mitral valve prolapse was present in only 2% of
the patients, despite the higher numbers (19%)
reported in the study by Strom et al. [11]. Only
three patients, suffering from eight-sided IE, had
a history of intravenous drug abuse, similar to the
proportion reported previously in a Swedish
university hospital [10]. Thirteen patients had
undergone dental manipulations during the past
3 months, compared with 23% in a previous
study [11]. However, dental procedures have not
been found previously to be a risk factor for
endocarditis [20–22], especially when there is no
known cardiac valve abnormality, since there is a
widespread practice of antibiotic prophylaxis
[20,21]. Eight (8%) patients mentioned a past
episode of IE, compared with 6–15% in previous
studies [7,11].
Staphylococci, streptococci and enterococci
remained the most frequent pathogens of IE,
causing > 61% of the cases in the present study.
In a more detailed analysis, viridans streptococci
were the most important pathogens in NVE,
responsible for 29% of cases. In PVE, S. aureus
and S. epidermidis were isolated from 10% and
16% of cases, respectively, and viridans strepto-
cocci from 6.5%; these numbers are slightly
lower compared to previous studies [11,23].
PME was caused almost entirely (91%) by S.
aureus and S. epidermidis. This ﬁnding is in
complete agreement with other PME series,
where staphylococci account for > 70% of cases
[8,14–17]. Among the S. aureus isolates, 27%
(15% in NVE, 67% in PVE, and 33% in PME)
were methicillin-resistant. These numbers are
much higher than the ﬁgures reported previ-
ously [8,24]. Similarly, 62.5% of S. epidermidis
isolates (43% in NVE, 100% in PVE, and 50% in
PME) were methicillin-resistant, also much high-
er than in other studies [8,15].
IE remains a serious disease requiring prompt
diagnosis and treatment. It is the fourth most
important life-threatening infectious syndrome
[4]. The role of early cardiosurgical intervention
in cases of cardiac complications (e.g., congestive
heart failure), endocardiac abscess, fungal endo-
carditis and failure of treatment is now accepted
widely [13]. Regarding PVE, many papers indi-
cate that early valve replacement results in signi-
ﬁcantly lower mortality compared to medical
treatment alone [23]. For cases involving S. aureus,
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this applies even to patients without cardiac
complications because of the aggressiveness of
the disease [1,24,25]. Surgical intervention is
necessary in fungal endocarditis [1–3]. In cases
of PME, the importance of the removal (intravas-
cular or thoracosurgical) of the whole PM device
as early as possible has been proven [8,14–18].
The high percentage of surgical intervention in
the present study, although related partly to the
selected population of the study (i.e., tertiary
hospital and cardiosurgery centre patients), re-
ﬂects the contemporary tendency of clinicians to
proceed with surgery in selected patients,
although these views are not universal.
The overall mortality in the present series
was 16%, compared with 9–35% in other series
[5–7,10,12]. The PVE mortality rate was 29% and,
although more than three-fold that of NVE,
this ﬁgure is among the lowest in the literature
[23–25]. One possible explanation is the high
percentage of surgical intervention, since medical
treatment alone resulted in a three-fold higher
mortality rate compared to combined medical and
surgical treatment (24.5% vs. 8%; p < 0.05). This
latter ﬁnding is consistent with the results of a
recent study by Netzer et al. [26], who concluded
that early surgical treatment was predictive of
improved overall long-term survival. However,
randomised studies rather than case series are
needed to conﬁrm these conclusions. It should
also be noted that mortality following surgical
treatment ranges between 5% and 26% in the
literature [9,27,28].
Compared to previous studies in the Greek
population [29,30], the present study revealed
changing trends in the epidemiology, microbio-
logy, treatment and prognosis of IE in Greece.
During the last 30 years there has been an
increase in the mean age of patients of 16 years
(from 38 to 54 years), a nine-fold decrease in
rheumatic heart disease (from 65% to 7%), a
decrease in Streptococcus viridans cases (from 48%
to 19%), an increase in cases involving Staphylo-
coccus spp. (from 22% to 38%), and an increase in
the proportion of PVE (from 9% to 31%). Also
notable was the emergence of PME during the last
15 years (an increase from <1% to 11%), and an
increase in the proportion of surgical intervention
(from 29.5% during the ﬁrst year to 51.5% during
the ﬁrst 3 months), followed by a decrease in
mortality (from 20% in-hospital mortality to 16%
during the ﬁrst 3 months).
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